Citations

Mayo Clinic

Clear

6048 citation(s) found for "Wu, Peter S".

Pathway analysis of primary central nervous system lymphoma
Personett, David, Baskerville, Karen A., Menke, David M. , Jaeckle, Kurt A. , Kreinest, Pamela, Edenfield, Brandy , Lai, Weil, Park, Peter J. , McKinney, Michael, Tun, Han W. , Zubair, Abba C. , O’Neill, Brian Patrick , Park, Peter J

Blood | January 10, 2008 | Volume: 111 | Issue: 6 | Pages: 3200-3210

10.1182/blood-2007-10-119099 | PMID 18184868 Get It

Abstract Primary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the CNS. A genome-wide gene expression comparison between PCNSL and non-CNS DLBCL was performed, the latter consisting of both nodal and extranodal DLBCL (nDLBCL and enDLBCL), to identify a “CNS signature.” Pathway analysis with the program SigPathway revealed that PCNSL is characterized notably by significant differential expression of multiple extracellular matrix (ECM) and adhesion-related pathways. The most significantly up-regulated gene is the ECM-related osteopontin (SPP1). Expression at the protein level of ECM-related SPP1 and CHI3L1 in PCNSL cells was demonstrated by immunohistochemistry. The alterations in gene expression can be interpreted within several biologic contexts with implications for PCNSL, including CNS tropism (ECM and adhesion-related pathways, SPP1, DDR1), B-cell migration (CXCL13, SPP1), activated B-cell subtype (MUM1), lymphoproliferation (SPP1, TCL1A, CHI3L1), aggressive clinical behavior (SPP1, CHI3L1, MUM1), and aggressive metastatic cancer phenotype (SPP1, CHI3L1). The gene expression signature discovered in our study may represent a true “CNS signature” because we contrasted PCNSL with wide-spectrum non-CNS DLBCL on a genomic scale and performed an in-depth bioinformatic analysis.
Renal Artery Intervention in Pediatric and Adolescent Patients: A 20-Year Experience
Huang, Ying , Duncan, Audra A. , McKusick, Michael A., Milliner, Dawn S. , Bower, Thomas C., Kalra, Manju , Gloviczki, Péter , Hoskin, Tanya L. , Gloviczki, Péter

Vascular and Endovascular Surgery | January 7, 2008 | Volume: 41 | Issue: 6 | Pages: 490-499

10.1177/1538574407307944 | PMID 18166629 Get It

Between 1986 and 2005, 22 patients (mean age, 14.7 years; range, 3-21) with renal hypertension underwent renal artery revascularization for 28 lesions, 23 with open repair (OR) and 5 with percutaneous transluminal renal angioplasty (PTRA). Thirty-day morbidity was 17% (4/23). Hypertension was cured in 13 (57%), improved in 8 (38%), and unchanged in 1 (5%). Renal function worsened in 1. At a mean follow-up of 4.9 years, 1-year patency rate was 94% and maintained for 5 years. Hypertension at 1 year was cured in 6 of 14 patients (43%; OR, 4; PTRA, 2) and improved in 8 (57%; OR, 7; PTRA, 1); hypertension at 5 years was cured in 50% and improved in 50%. Renal function remained unchanged in all patients who were followed. The authors conclude that both OR and PTRA benefit pediatric patients. PTRA for selected patients may be promising as a first line treatment or as a bridge to definitive OR in children with small arteries.
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
Qiao, Jian , Wang, Hongxun , Kottke, Timothy, Twigger, Katie, Díaz, Rosa María, Thompson, Jill , Selby, Peter J. , Bono, Johann S. de , Melcher, Alan , Pandha, Hardev , Vile, Richard G. , Harrington, Kevin J. , White, Christine L. , Coffey, Matt C. , Melcher, Alan A , Harrington, Kevin , de Bono, Johann

Clinical Cancer Research | January 3, 2008 | Volume: 14 | Issue: 1 | Pages: 259-269

10.1158/1078-0432.ccr-07-1510 | PMID 18172278 Get It

Abstract Purpose: The purpose of the present study was to investigate whether it is possible to achieve truly systemic delivery of oncolytic reovirus, in immunocompetent hosts, using cyclophosphamide to overcome some of the barriers to effective intratumoral delivery and replication of i.v. injected virus. Experimental Design: I.v. delivery of reovirus was combined with different regimens of i.p. administered cyclophosphamide in C57Bl/6 mice bearing established s.c. B16 tumors. Intratumoral viral replication, tumor size, and survival were measured along with levels of neutralizing antibody (NAb) in the blood. Finally, differential toxicities of the virus/cyclophosphamide regimens were monitored through viral replication in systemic organs, survival, and cardiac damage. Results: Repeated i.v. injection of reovirus was poorly effective at seeding intratumoral viral replication/oncolysis. However, by combining i.v. virus with cyclophosphamide, viral titers of between 107 and 108 plaque-forming units per milligram were recovered from regressing tumors. Doses of cyclophosphamide that ablated NAb were associated with severe toxicities, characterized by viral replication in systemic organs—toxicities that are mirrored by repeated reovirus injections into B-cell knockout mice. Next, we restructured the dosing of cyclophosphamide and i.v. virus such that a dose of 3 mg cyclophosphamide was administered 24 h before reovirus injection, and this schedule was repeated every 6 days. Using this protocol, high levels of intratumoral viral access and replication (∼107 plaque-forming units per milligram tumor) were maintained along with systemically protective levels of NAb and only very mild, non–life-threatening toxicity. Conclusion: NAb to oncolytic viruses play a dual role in the context of systemic viral delivery; on one hand, they hinder repeated administration of virus but on the other, they provide an important safety mechanism by which virus released from vigorous intratumoral replication is neutralized before it can disseminate and cause toxicity. These data support the use of cyclophosphamide to modulate, but not ablate, patient NAb, in development of carefully controlled clinical trials of the systemic administration of oncolytic viruses.
Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer
Kottke, Timothy, Sánchez-Pérez, Luis, Díaz, Rosa María, Thompson, Jill , Chong, Heung, Harrington, Kevin J. , Calderwood, Stuart K. , Pulido, José S. , Georgopoulos, Nick, Selby, Peter J. , Melcher, Alan , Vile, Richard G. , Georgopoulos, Nick, Melcher, Alan A , Harrington, Kevin

Cancer Research | December 18, 2007 | Volume: 67 | Issue: 24 | Pages: 11970-11979

10.1158/0008-5472.can-07-2259 | PMID 18089828 Get It

AbstractA close connectivity between autoimmune and tumor rejection responses is known to exist in the case of melanoma immunotherapy. However, relatively little is known about self-antigens on other types of normal cells, their relation to the development of autoimmune disease, and their possible coexistence as potential tumor rejection antigens on associated tumors. In the current study, we induced inflammatory killing of normal prostate tissue in situ using a fusogenic membrane glycoprotein along with the immune adjuvant hsp70. We show here that, in the prostate, hsp70 induces interleukin (IL)-6, which triggers a CD4- and CD8-dependent progressive autoimmune reactivity, associated with IL-17 expression. This autoimmune response was also able to induce the rejection of established prostate tumors, but not other histologic types of tumors, growing elsewhere in the animal. These data show that the intimate connectivity between autoimmune and tumor rejection responses extends beyond the classic melanoma paradigm and may be clinically valuable for the treatment of established metastatic disease of the prostate. [Cancer Res 2007;67(24):11970–9]
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/m
Goldstone, Anthony H., Richards, Susan , Tallman, Martin S. , Buck, Georgina , Burnett, Alan K. , Chopra, Raj, Wiernik, Peter H. , Foroni, Letizia, Paietta, Elisabeth , Litzow, Mark R. , Marks, David I. , Durrant, Jill, McMillan, Andrew , Franklin, Ian M., Luger, Selina M. , Ciobanu, Niculae, Rowe, Jacob M. , Lazarus, Hillard M. , Fielding, Adele K. , Franklin, Ian M.

Blood | November 29, 2007 | Volume: 111 | Issue: 4 | Pages: 1827-1833

10.1182/blood-2007-10-116582 | PMID 18048644 Get It

An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy. Patients received 2 phases of induction and, if in remission, were assigned to allogeneic transplantation if they had a compatible sibling donor. Other patients were randomized to chemotherapy for 2.5 years versus an autologous transplantation. A donor versus no-donor analysis showed that Philadelphia chromosome–negative patients with a donor had a 5-year improved overall survival (OS), 53% versus 45% (P = .01), and the relapse rate was significantly lower (P ≤ .001). The survival difference was significant in standard-risk patients, but not in high-risk patients with a high nonrelapse mortality rate in the high-risk donor group. Patients randomized to chemotherapy had a higher 5-year OS (46%) than those randomized to autologous transplantation (37%; P = .03). Matched related allogeneic transplantations for ALL in first complete remission provide the most potent antileukemic therapy and considerable survival benefit for standard-risk patients. However, the transplantation-related mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse risk. There is no evidence that a single autologous transplantation can replace consolidation/maintenance in any risk group. This study is registered at http://clinicaltrials.gov as NCT00002514.
Endoscopic Perforator Vein Surgery: Does It Work?
Gloviczki, Péter , Gloviczki, Péter

Vascular Surgery | November 26, 2007 | Volume: 32 | Issue: 4 | Pages: 303-305

10.1177/153857449803200401 Get It

Laparotomy for Presumed Ruptured Abdominal Aortic Aneurysm: Outcome of Deceptive Emergencies
Melin, Matthew M , Gloviczki, Péter , Cherry, Kenneth J., Bower, Thomas C., Hallett, John W., Baerga, Yvonne, Zietlow, Scott P., Stanson, Anthony W., Gloviczki, Péter

Vascular Surgery | November 26, 2007 | Volume: 31 | Issue: 5 | Pages: 523-530

10.1177/153857449703100503 Get It

Medical and surgical emergencies occasionally present as ruptured abdominal aortic aneurysms (RAAA). To assess benefits of laparotomies and adverse effects of unnecessary operations, the authors reviewed their experience. Thirteen patients, 9 women, 4 men (mean age: 72 years, range: 41-85) underwent emergency laparotomy between 1988 and 1996 for presumed RAAA and were found to have other surgical or medical emergencies. All the patients presented with hypotension, 12 had abdominal or back pain, four had pulsatile abdominal mass. Rupture was not excluded by computed tomography scan in three or by ultrasonography in two patients. Laparotomy disclosed intact abdominal aorta in all, but seven patients had abdominal aortic aneurysm. Of five surgical emergencies, laparotomy was indicated in four: three for ruptured visceral artery aneurysms, one for perforated duodenal ulcer. The fifth patient required thoracotomy for ruptured thoracic aneurysm. Four of eight medical emergencies were myocardial infarctions. One iatro genic complication required reoperation for bleeding. Mean hospital stay was 18 days; mean hospital charges were $40,771. Seven (54%) early deaths occurred; none were caused directly by the operation. Laparotomy was indicated in one third of deceptive emergencies that present as RAAA. Although mortality, morbidity, and costs were high, iatrogenic surgical complica tions were rare and deaths were not caused by unnecessary operations.
The Case for Aggressive Treatment
Gloviczki, Péter , Canton, Linda G., Bower, Thomas C., Cherry, Kenneth J., Hallett, John W., Stanson, Anthony W., Pairolero, Peter C., Gloviczki, Péter

Vascular Surgery | November 26, 2007 | Volume: 31 | Issue: 3 | Pages: 319-320

10.1177/153857449703100343 Get It

Endoscopic Treatment of Incompetent Perforators
Gloviczki, Péter , Canton, Linda G., Menawat, Sunil S., Mózes, Gèza, Lindsey, J. Russell, Lewis, Blaine, Gloviczki, Péter

Vascular Surgery | November 26, 2007 | Volume: 31 | Issue: 3 | Pages: 267-268

10.1177/153857449703100324 Get It

Atrophy rates accelerate in amnestic mild cognitive impairment
Jack, Clifford R. , Weigand, Stephen D. , Shiung, Maria M., Przybelski, Scott A. , O’Brien, Peter C. , Gunter, Jeffrey L. , Smith, Glenn E. , Petersen, Ronald C. , Knopman, David S. , Boeve, Bradley F. , Jack, Clifford R

Neurology | November 22, 2007 | Volume: 70 | Issue: 19_part_2 | Pages: 1740-1752

10.1212/01.wnl.0000281688.77598.35 | PMID 18032747 Get It